YinlitinibAlternative Names: Yinlitinib maleate
Latest Information Update: 25 Aug 2016
At a glance
- Originator HEC Pharm
- Class Antineoplastics; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 25 Aug 2015 Preclinical trials in Solid tumours in China (unspecified route) prior to August 2016 (HEC Pharma pipeline, August 2016)